Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age
Trial status:Study Complete
Trial ID:
C4591030
NCT ID:
EudraCT ID:
N/A
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
BioNTech SE
Study Complete
Trial Details
This study will assess the safety and immunogenicity of a fourth dose (booster) of BNT162b2 when coadministered with SIIV compared to separate administration of the vaccines when given 1 month apart (SIIV followed by BNT162b2), in participants who have received 3 prior doses of 30 µg BNT162b2, with the third dose being at least 90 days before Visit 1 (Day 1). * Healthy adults 18 through 64 years of age will be randomized 1:1 to either the co-administration group, or the separate administration group * The duration of the study for each participant will be approximately 2 months * There are 3 scheduled study visits each about 1 month apart * The study will be conducted in New Zealand and Australia.
Medical Condition
Trial Drug
See more
Phase
Phase 3
Type
Interventional
Estimated Enrolment
1134
Estimated Trial Date
Apr 2022 - Oct 2022
Trial Participant Requirements
Age
18 - 64 Years
Sex
Female & Male
Healthy Volunteers
Yes
Trial Locations
Location
Status
Location
Northern Beaches Clinical Research
Brookvale, New South Wales, Australia, 2100
Status
Location
Australian Clinical Research Network
Sydney, New South Wales, Australia, NSW 2035
Status
Location
Westmead Hospital
Westmead, New South Wales, Australia, 2145
Status
Location
Paratus Clinical Research Brisbane
Albion, Queensland, Australia, 4010
Status
Location
AusTrials - Wellers Hill
Wellers Hill, Queensland, Australia, 4121
Status
Location
Emeritus Research
Camberwell, Victoria, Australia, 3124
Status